|
GB8808015D0
(en)
|
1988-04-06 |
1988-05-05 |
Ritter M A |
Chemical compounds
|
|
WO1990005183A1
(en)
|
1988-10-31 |
1990-05-17 |
Immunex Corporation |
Interleukin-4 receptors
|
|
EP0668774A1
(en)
|
1991-05-03 |
1995-08-30 |
Seragen, Inc. |
Interleukin receptor targeted molecules for treatment of inflammatory arthritis
|
|
JP3315427B2
(ja)
|
1992-03-05 |
2002-08-19 |
大日本除蟲菊株式会社 |
皮膚炎治療剤
|
|
US5714146A
(en)
|
1992-08-26 |
1998-02-03 |
Board Of Regents Of The University Of Washington |
IL-4 bone therapy
|
|
EP0604693A1
(en)
|
1992-12-29 |
1994-07-06 |
Schering-Plough |
Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
|
|
RU2162711C2
(ru)
|
1993-09-07 |
2001-02-10 |
Смитклайн Бичам Корпорейшн |
Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
|
|
JP2003524602A
(ja)
|
1998-09-18 |
2003-08-19 |
ダイナバックス テクノロジーズ コーポレイション |
ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
|
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
|
PT2990420T
(pt)
|
2000-05-26 |
2017-03-16 |
Immunex Corp |
Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
ATE372764T1
(de)
|
2000-07-26 |
2007-09-15 |
Hououdou Co Ltd |
Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen
|
|
WO2002051437A1
(en)
|
2000-12-22 |
2002-07-04 |
Societe Des Produits Nestle S.A. |
Induction of tolerance
|
|
US20030103938A1
(en)
|
2001-05-09 |
2003-06-05 |
Alk-Abello A/S |
Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
|
|
WO2002092125A1
(en)
|
2001-05-11 |
2002-11-21 |
Novartis Ag |
Compositions for use in treating ige-associated disorders
|
|
CA2447795A1
(en)
|
2001-05-23 |
2002-11-28 |
Duotol Ab |
Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
|
|
EP2990394A1
(en)
|
2001-11-30 |
2016-03-02 |
Biogen MA Inc. |
Antibodies against monocyte chemotactic proteins
|
|
ES2327830T3
(es)
|
2002-03-29 |
2009-11-04 |
Schering Corporation |
Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
|
|
WO2004047793A1
(en)
|
2002-11-26 |
2004-06-10 |
Alk-Abelló A/S |
Pharmaceutical allergen product
|
|
WO2004070010A2
(en)
|
2003-02-01 |
2004-08-19 |
Tanox, Inc. |
A method for generating high affinity antibodies
|
|
US7923209B2
(en)
|
2003-03-14 |
2011-04-12 |
Anergis, S.A. |
Allergen peptide fragments and use thereof
|
|
UA93653C2
(ru)
|
2003-11-07 |
2011-03-10 |
Иммунекс Корпорейшн |
Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
|
|
AU2004309373A1
(en)
|
2003-12-22 |
2005-07-14 |
Amgen Inc. |
Methods for identifying functional antibodies
|
|
WO2005085284A1
(en)
|
2004-02-27 |
2005-09-15 |
Regeneron Pharmaceuticals, Inc. |
Il-4/il-13 sepecific polypetides and therapeutic uses thereof
|
|
AR049390A1
(es)
*
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
US20090098142A1
(en)
|
2004-06-09 |
2009-04-16 |
Kasaian Marion T |
Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
|
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
|
JP5234445B2
(ja)
|
2004-10-05 |
2013-07-10 |
源一郎 杣 |
薬剤
|
|
WO2006083390A2
(en)
|
2004-12-07 |
2006-08-10 |
Children's Hospital Medical Center |
Eotaxin-3 in eosinophilic esophagitis
|
|
TWI306862B
(en)
|
2005-01-03 |
2009-03-01 |
Hoffmann La Roche |
Antibodies against il-13 receptor alpha 1 and uses thereof
|
|
CN101198624B
(zh)
|
2005-05-06 |
2012-10-10 |
津莫吉尼蒂克斯公司 |
Il-31单克隆抗体及使用方法
|
|
US8324192B2
(en)
|
2005-11-12 |
2012-12-04 |
The Regents Of The University Of California |
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
|
|
US8679545B2
(en)
|
2005-11-12 |
2014-03-25 |
The Regents Of The University Of California |
Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
|
|
ATE537190T1
(de)
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
Hochaffine antikörper gegen den humanen il-6- rezeptor
|
|
JP4221018B2
(ja)
|
2006-08-31 |
2009-02-12 |
トヨタ自動車株式会社 |
頭部保護エアバッグ装置
|
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
CA2664343C
(en)
|
2006-10-02 |
2016-04-26 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human il-4 receptor
|
|
PL2132230T3
(pl)
|
2007-03-22 |
2014-09-30 |
Genentech Inc |
Apoptotyczne przeciwciała anty-IgE wiążące IgE związaną z błoną
|
|
EP2022507A1
(en)
|
2007-08-07 |
2009-02-11 |
Universität Hamburg |
Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
|
|
US8637239B2
(en)
|
2007-11-05 |
2014-01-28 |
The Board Of Trustees Of The University Of Illinois |
Minimally-invasive measurement of esophageal inflammation
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
DE202008006598U1
(de)
|
2008-04-11 |
2008-10-02 |
Alk-Abelló A/S |
Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
|
|
US20090264392A1
(en)
|
2008-04-21 |
2009-10-22 |
Meritage Pharma, Inc. |
Treating eosinophilic esophagitis
|
|
CA2748712A1
(en)
|
2008-12-01 |
2010-06-10 |
Children's Hospital Medical Center |
Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
|
|
EP2414520A2
(en)
|
2009-03-31 |
2012-02-08 |
Altair Therapeutics, Inc. |
Methods of modulating an immune response to a viral infection
|
|
US8497528B2
(en)
|
2010-05-06 |
2013-07-30 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Method for fabricating a strained structure
|
|
CN102596237A
(zh)
|
2009-09-07 |
2012-07-18 |
Dbv技术公司 |
治疗嗜酸细胞性食管炎的方法
|
|
US8993347B2
(en)
*
|
2009-12-17 |
2015-03-31 |
Cornell University |
Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
|
|
US20120164080A1
(en)
|
2010-06-24 |
2012-06-28 |
Meritage Pharma, Inc. |
Methods of treatment for esophageal inflammation
|
|
MX366337B
(es)
|
2010-10-06 |
2019-07-05 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
|
|
CN105859889B
(zh)
|
2010-11-17 |
2020-01-07 |
中外制药株式会社 |
具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
|
|
RU2453303C1
(ru)
|
2010-12-23 |
2012-06-20 |
Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") |
Фармацевтическая композиция для лечения атопического дерматита
|
|
US20130324435A1
(en)
|
2011-01-06 |
2013-12-05 |
Children's Hospital Medical Center |
Esophageal cytokine expression profiles in eosinophilic esophagitis
|
|
US20130052190A1
(en)
|
2011-02-22 |
2013-02-28 |
Oxagen Limited |
CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
|
|
US9928344B2
(en)
|
2011-06-21 |
2018-03-27 |
Children's Hospital Medical Center |
Diagnostic methods of eosinophilic esophagitis
|
|
US8790651B2
(en)
|
2011-07-21 |
2014-07-29 |
Zoetis Llc |
Interleukin-31 monoclonal antibody
|
|
CN103974706A
(zh)
|
2011-10-06 |
2014-08-06 |
N·V·努特里奇亚 |
嗜酸细胞性食管炎的治疗
|
|
CN104114169A
(zh)
|
2011-12-16 |
2014-10-22 |
阿托佩斯治疗有限公司 |
用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
|
|
WO2013116287A1
(en)
|
2012-01-31 |
2013-08-08 |
Genentech, Inc. |
Anti-ig-e m1' antibodies and methods using same
|
|
WO2013155010A1
(en)
|
2012-04-09 |
2013-10-17 |
Children's Hospital Medical Center |
Non-invasive biomarkers for eosinophilic esophagitis
|
|
US9999628B2
(en)
*
|
2012-05-14 |
2018-06-19 |
Antecip Bioventures Ii Llc |
Neridronic acid for treating complex regional pain syndrome
|
|
KR102502640B1
(ko)
|
2012-08-21 |
2023-02-23 |
사노피 바이오테크놀로지 |
Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
|
|
CN118286417A
(zh)
*
|
2012-09-07 |
2024-07-05 |
瑞泽恩制药公司 |
以il-4r拮抗剂治疗特应性皮炎的方法
|
|
US10132809B2
(en)
|
2012-10-10 |
2018-11-20 |
Rhote Island Hospital |
Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
|
|
JP6636803B2
(ja)
|
2013-02-05 |
2020-01-29 |
エンクマフ エスアーエールエル |
Ｂｃｍａに対する抗体の選択のための方法
|
|
TWI755763B
(zh)
|
2013-06-04 |
2022-02-21 |
美商再生元醫藥公司 |
藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
RS59354B1
(sr)
|
2013-06-21 |
2019-10-31 |
Sanofi Biotechnology |
Postupci lečenja nosne polipoze davanjem il-4r antagonista
|
|
TWI634900B
(zh)
|
2013-07-11 |
2018-09-11 |
再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
RU2552929C1
(ru)
|
2013-11-14 |
2015-06-10 |
Общество С Ограниченной Ответственностью "Фарминтерпрайсез" |
Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
PT3110848T
(pt)
|
2014-09-24 |
2024-03-05 |
Regeneron Pharma |
Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
|
|
CA3246946A1
(en)
*
|
2014-11-14 |
2025-11-29 |
Sanofi Biotechnology |
Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
|
|
EP3416685B1
(en)
|
2016-02-19 |
2024-06-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist
|
|
TWI777515B
(zh)
|
2016-08-18 |
2022-09-11 |
美商愛戴爾製藥股份有限公司 |
治療嗜伊紅性食道炎之方法
|
|
KR102872485B1
(ko)
|
2016-09-01 |
2025-10-20 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
|
|
RU2759630C2
(ru)
|
2016-09-22 |
2021-11-16 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения тяжелого атопического дерматита путем введения ингибитора il-4r
|
|
IL268349B2
(en)
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2019028367A1
(en)
|
2017-08-04 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
|
|
PT3515465T
(pt)
|
2017-08-18 |
2024-03-04 |
Regeneron Pharma |
Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
|
|
US11034768B2
(en)
|
2017-10-30 |
2021-06-15 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an IL-4R antagonist
|
|
MX2020012064A
(es)
|
2018-05-13 |
2021-04-13 |
Regeneron Pharma |
Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r.
|
|
EP4406975A3
(en)
|
2018-06-14 |
2024-11-13 |
Ajinomoto Co., Inc. |
Compound having affinity substance to antibody and bioorthogonal functional group, or salt thereof
|
|
KR20210143246A
(ko)
|
2019-03-21 |
2021-11-26 |
리제너론 파아마슈티컬스, 인크. |
알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
|
|
MX2021013427A
(es)
|
2019-05-01 |
2022-01-31 |
Sanofi Biotechnology |
Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
|
|
JP7736667B2
(ja)
|
2019-08-05 |
2025-09-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法
|
|
US11504426B2
(en)
|
2019-08-05 |
2022-11-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
|
|
CA3161037A1
(en)
|
2019-12-09 |
2021-06-17 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
|
KR20220158821A
(ko)
|
2020-03-27 |
2022-12-01 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
|
|
JP7862322B2
(ja)
|
2020-05-22 |
2026-05-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法
|
|
US20220169739A1
(en)
|
2020-10-05 |
2022-06-02 |
Sanofi Biotechnology |
Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
|
|
US20220220211A1
(en)
|
2021-01-08 |
2022-07-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
|